Qfitlia is a drug owned by Genzyme Corp. It is protected by 3 US drug patents filed in 2025 out of which none have expired yet. Qfitlia's patents will be open to challenges from 28 March, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 07, 2036. Details of Qfitlia's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9127274 | Serpinc1 iRNA compositions and methods of use thereof |
Mar, 2033
(7 years from now) | Active |
| US9376680 | Serpinc1 iRNA compositions and methods of use thereof |
Mar, 2033
(7 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11091759 | Methods and compositions for treating a Serpinc1-associated disorder |
Dec, 2036
(11 years from now) | Active |
FDA has granted several exclusivities to Qfitlia. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Qfitlia, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Qfitlia.
Exclusivity Information
Qfitlia holds 3 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2032. Details of Qfitlia's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 28, 2030 |
| Orphan Drug Exclusivity(ODE-510) | Mar 28, 2032 |
| Orphan Drug Exclusivity(ODE-511) | Mar 28, 2032 |
US patents provide insights into the exclusivity only within the United States, but Qfitlia is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qfitlia's family patents as well as insights into ongoing legal events on those patents.
Qfitlia's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Qfitlia's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 07, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qfitlia Generics:
There are no approved generic versions for Qfitlia as of now.
About Qfitlia
Qfitlia is a drug owned by Genzyme Corp. Qfitlia uses Fitusiran Sodium as an active ingredient. Qfitlia was launched by Genzyme Corp in 2025.
Approval Date:
Qfitlia was approved by FDA for market use on 28 March, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Qfitlia is 28 March, 2025, its NCE-1 date is estimated to be 28 March, 2029.
Active Ingredient:
Qfitlia uses Fitusiran Sodium as the active ingredient. Check out other Drugs and Companies using Fitusiran Sodium ingredient
Dosage:
Qfitlia is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML) | SOLUTION | Prescription | SUBCUTANEOUS |
| EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML) | SOLUTION | Prescription | SUBCUTANEOUS |